Psyomics secures £2.4m Series B investment led by Parkwalk to expand mental health platform.
Parkwalk led the Series B financing, with participation from Meltwind, Newable Ventures and BGF, to widen access to the Censeo platform.
Share allotment filed at Companies House
Psyomics is a Cambridge spinout that develops artificial intelligence software to streamline mental health assessments and triage. Its platform Censeo builds detailed patient profiles to guide clinical treatment pathways.
Psyomics has secured £2.4m in a Series B funding round led by Parkwalk. The financing also saw participation from Meltwind, Newable Ventures and existing backer BGF.
The capital will support the company as it expands access to its online mental health assessment platform, Censeo, for individual users and NHS trusts. The platform mirrors a face to face psychiatric evaluation to help clinicians make faster and more efficient decisions regarding patient care.
The fresh injection of funds follows a pilot programme across general practice surgeries and precedes new projects rolling out within NHS treatment providers.
From the founder
"The continued support from Parkwalk, Meltwind and BGF alongside new investment from Newable Ventures enables us to expand the reach of Censeo, helping more people who are struggling to find the right support for their mental health needs. We’re excited to grow our team, expand further across the NHS and demonstrate with our partners that our technology can make a substantial difference in the accuracy, consistency and efficiency of mental health assessments in a wide range of clinical settings."
Stephanie Martlew
CEO at Psyomics
Investor perspective
"Recent years have shown how important digital health solutions are across the board to help confront the growing challenges facing the healthcare system. Psyomics’ clinical and tech-led assessment tool will help to transform the way mental health is diagnosed and the expansion of their platform within the NHS and to individual patients is a testament to their success. We’re proud to have been working with their team from the early-stages and look forward to seeing Psyomics continue to develop their platform and grow in the years to come."
Martin Glen
Investment Director, Parkwalk
Use of funds
- 01Grow the team
- 02Continue product development
- 03Expand into international markets
Investors
Categories
About the company
Psyomics
Psyomics develops artificial intelligence software to improve mental health assessment and diagnosis.